Back to Results
First PageMeta Content
Chemistry / Cell biology / Medical tests / Blood tests / Leukemia / Minimal residual disease / Flow cytometry / Cytometry / Assay / Biology / Medicine / Laboratory techniques


LeukoDx receives 1st year Chief Scientist grant for 40% of $660,000 R&D budget LeukoDx is developing, Accellix, its fully automated flow cytometer, to provide rapid diagnostic information for Leukemia Patients. Jerusale
Add to Reading List

Document Date: 2014-06-09 03:39:10

Open Document

File Size: 105,70 KB

Share Result on Facebook

City

Jerusalem / /

Company

LeukoDx Ltd. / Trillium Diagnostics / /

Country

Israel / /

Currency

USD / /

/

Event

FDA Phase / Reorganization / /

IndustryTerm

healthcare resources / technology development / biotechnology / microflow cytometer systems / /

MedicalCondition

Leukemia / minimal residual disease / sepsis / /

Organization

National Aeronautics and Space Administration / LeukoDx’s mission / /

/

Position

Chief Scientist / Julien Meissonnier President and CEO / 1st year Chief Scientist / /

Product

Accellix platform / NIS2 / Accellix / /

Technology

laser / biotechnology / /

SocialTag